FDA-approved Cobenfy offers a novel treatment for schizophrenia, targeting cholinergic receptors instead of dopamine, with ...

“The dopamine hypothesis proposed that schizophrenia is associated with excessive dopamine neurotransmission — so too much dopamine activity,” says Dr. Ann Shinn, a psychiatrist who directs ...

Here's Dr. Ann Shinn, a psychiatrist who directs clinical research on schizophrenia and bipolar disorder at McLean Hospital near Boston. ANN SHINN: The dopamine hypothesis proposed that ...

Atypical antipsychotic drugs have been shown to be more efficacious in treating cognitive disturbances of schizophrenia compared with typical antipsychotic drugs. Serotonin (5-hydroxytryptamine [5 ...

While schizophrenia treatments primarily target the dopamine neurotransmitter system in the brain, Cobenfy goes after a ...

the dopaminergic hypothesis of schizophrenia has formed the basis of the schizophrenia treatment paradigm, whereby atypical antipsychotics target the abnormally elevated concentration of dopamine ...

Until now, all available antipsychotics have worked by blocking a dopamine receptor. In most patients with schizophrenia, they can reduce symptoms like hallucinations and paranoia to a manageable ...

26 (UPI) --The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia ... brain's cholinergic receptors instead of dopamine receptors, which have been the ...